IMMUNE RESPONSE CORP
EXHIBIT 10.1
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>a2083790zex-10_1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
<TITLE>
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#02SAN1582_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="kg1582_exhibit_10.1"> </A>
<A NAME="toc_kg1582_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit 10.1    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kg1582_amendment_no._3_to_lice__kg102094"> </A>
<A NAME="toc_kg1582_2"> </A>
<BR></FONT><FONT SIZE=2><B>AMENDMENT NO. 3 TO LICENSE AND COLLABORATION AGREEMENT    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>THIS AMENDMENT NO. 3 TO LICENSE AND COLLABORATION AGREEMENT</B></FONT><FONT SIZE=2> (this "Amendment"), effective as of June 26, 2002 (the
"Effective Date") is entered into by and between </FONT><FONT SIZE=2><B>THE IMMUNE RESPONSE CORPORATION</B></FONT><FONT SIZE=2>, a Delaware corporation ("IRC"), and </FONT><FONT SIZE=2><B>TRINITY
MEDICAL GROUP USA,&nbsp;INC.</B></FONT><FONT SIZE=2>, a Florida corporation ("Trinity"), with respect to the following facts. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>RECITALS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;&nbsp;&nbsp;&nbsp;IRC
and Trinity Medical Group, Co.,&nbsp;Ltd., a Thai limited company ("Trinity Thailand"), entered into the License and Collaboration Agreement dated as of
September&nbsp;15, 1995, which was amended on September&nbsp;29, 2000, by the Amendment No.&nbsp;1 to License and Collaboration Agreement, and on May&nbsp;8, 2001, by the Amendment
No.&nbsp;2 to License and Collaboration Agreement (collectively the "Agreement"). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Assignment Agreement dated as of August&nbsp;3, 2000, between Trinity Thailand and Trinity, Trinity Thailand assigned to Trinity and Trinity assumed,
all of Trinity Thailand's rights and obligations under the Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;&nbsp;&nbsp;&nbsp;The
parties now desire to amend the Agreement on the terms and conditions set forth below. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D.&nbsp;&nbsp;&nbsp;&nbsp;In
consideration for amending the Agreement, IRC shall issue up to 7,000,000 shares of its common stock to Trinity upon the terms and conditions set forth below. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the parties amend the Agreement and otherwise agree as follows: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE 1<BR>
AMENDMENT OF AGREEMENT  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1&nbsp;&nbsp;Section&nbsp;6.3.1(c)
of the Agreement shall be restated in its entirety to read as follows: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;With
respect to commercial supply under Section&nbsp;6.1.2 above, Trinity shall purchase Product from IRC at the following purchase price per dose (the "Purchase
Price"): </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;For
each dose of Product purchased by Trinity under Section&nbsp;6.1.2 through the first to occur of the purchase by Trinity under Section&nbsp;6.1.2 of one million
(1,000,000) doses of Product in the aggregate, and December&nbsp;31, 2007, the Purchase Price shall equal the sum of (A)&nbsp;one hundred ten percent (110%) of IRC's Manufacturing Cost for such
dose of Product, plus (B)&nbsp;US$50.00; provided, however that the Purchase Price under this Section&nbsp;6.3.1(c)(i)&nbsp;shall not exceed US$132.00. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;For
each dose of Product purchased by Trinity under Section&nbsp;6.1.2 following the first to occur of the purchase by Trinity under Section&nbsp;6.1.2 of one
million (1,000,000) doses of Product in the aggregate, and December&nbsp;31, 2007, the Purchase Price shall equal one hundred ten percent (110%) of IRC's Manufacturing Cost for such dose of Product. </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2&nbsp;&nbsp;Section&nbsp;6.6.1
of the Agreement shall be restated in its entirety to read as follows: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Delivery</I></FONT><FONT SIZE=2>. IRC's obligation to deliver Products under this Agreement shall be subject to obtaining all necessary consents, approvals,
authorizations and licenses of the applicable governmental and regulatory authorities for the manufacture, export and delivery of Products under this Agreement. IRC shall use commercially reasonable
efforts to obtain such necessary consents, approvals, authorizations and licenses, and Trinity shall cooperate with IRC in obtaining such consents, approvals, authorizations and licenses. IRC's
obligation to deliver Products under this Agreement additionally shall be subject to IRC having sufficient validated and operational manufacturing capacity to satisfy Trinity's reasonably foreseeable
forecasted requirements for </FONT></P>

</UL>
<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2083790",CP="THE IMMUNE RESPONSE CORPORATION",DN="2",CHK=617705,FOLIO='blank',FILE='DISK038:[02SAN2.02SAN1582]KG1582A.;3',USER='CBABB',CD=';3-JUL-2002;14:17' -->
<A NAME="page_kg1582_1_2"> </A>
<UL>

<P><FONT SIZE=2>
Products in the Territory for use in the Field. IRC shall use commercially reasonable efforts to cause its manufacturing facility for Products to have sufficient validated and operational capacity to
meet the reasonably foreseeable forecasted demand requirements of Trinity for Products as soon as reasonably feasible following marketing approval of Products in the Territory for use in the Field.
All Products supplied under the Agreement shall be shipped f.o.b. place of manufacture. Title and risk of loss and damages to the Products shall pass to Trinity upon release to Trinity's designated
carrier. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE 2<BR>
ISSUE OF IRC SHARES  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1&nbsp;&nbsp;On
the terms and conditions of this Amendment, IRC shall issue to Trinity the following number, up to an aggregate of seven million (7,000,000), of shares of IRC's
common stock (the "Shares") upon achievement of the following milestones (each a "Closing"): </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.1&nbsp;&nbsp;&nbsp;&nbsp;IRC
shall issue to Trinity four million (4,000,000) of the Shares on the Effective Date. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.2&nbsp;&nbsp;&nbsp;&nbsp;IRC
shall issue to Trinity one million (1,000,000) of the Shares within thirty days following the date on which Trinity purchases under Section&nbsp;6.1.2 of the
Agreement, and irrevocably pays to IRC the applicable Purchase Price for, an aggregate of three hundred thousand (300,000) doses of Product. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.3&nbsp;&nbsp;&nbsp;&nbsp;IRC
shall issue to Trinity one million (1,000,000) of the Shares within thirty days following the date on which Trinity purchases under Section&nbsp;6.1.2 of the
Agreement, and irrevocably pays to IRC the applicable Purchase Price for, an aggregate of six hundred thousand (600,000) doses of Product. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.4&nbsp;&nbsp;&nbsp;&nbsp;IRC
shall issue to Trinity one million (1,000,000) of the Shares within thirty days following the date on which Trinity purchases under Section&nbsp;6.1.2 of the
Agreement, and irrevocably pays to IRC the applicable Purchase Price for, an aggregate of one million (1,000,000) doses of Product. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2&nbsp;&nbsp;IRC's
obligation to issue the Shares pursuant to this Article&nbsp;2 shall terminate, with respect to all Shares not previously issued pursuant to this
Article&nbsp;2, on December&nbsp;31, 2007. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3&nbsp;&nbsp;For
purposes of this Amendment, "Share" or "Shares" refers to the class of common stock of IRC in existence as of May&nbsp;30, 2002. Any subsequent split of the Shares
as authorized by the stockholders of IRC shall increase or decrease the number of Shares that remain to be issued pursuant to this Article&nbsp;2 by the same factor as the split is computed. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4&nbsp;&nbsp;As
a condition precedent to the effectiveness of this Amendment, the parties shall have duly executed and delivered Amendment No.&nbsp;1 to Stock Purchase Agreement,
dated as of the Effective Date, which shall: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4.1&nbsp;&nbsp;&nbsp;&nbsp;Eliminate
Trinity's $5,000,000 stock purchase commitment which would have arisen upon IRC's transfer of certain manufacturing technology to Trinity; and </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4.2&nbsp;&nbsp;&nbsp;&nbsp;Reduce
the per share cost from $15 to $2.50 for Trinity's $5,000,000 stock purchase commitment which arises on the date that is thirty (30)&nbsp;days after the date
on which Trinity receives the required marketing approval from the governing health authority of Thailand for the Product. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2083790",CP="THE IMMUNE RESPONSE CORPORATION",DN="2",CHK=289847,FOLIO='2',FILE='DISK038:[02SAN2.02SAN1582]KG1582A.;3',USER='CBABB',CD=';3-JUL-2002;14:17' -->
<A NAME="page_kg1582_1_3"> </A>
<UL>
<BR>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE 3<BR>
REGISTRATION RIGHTS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the request of Trinity, IRC agrees to file up to four registration statements under the Securities Act of 1933, as amended (the "Act"), with the Securities and
Exchange Commission ("SEC") to register the Shares issued pursuant to Article&nbsp;2 of this Amendment, as soon as practicable after receipt of the request from Trinity following the respective
Closings. IRC shall use reasonable commercial efforts to respond to comments of the SEC within ten (10)&nbsp;business days of receipt of said comments and will use commercially reasonable efforts to
cause the registration statement to be declared effective by the SEC within ninety (90)&nbsp;days of the receipt of the request from Trinity. IRC shall keep the registration statement continuously
effective until the date occurring one year following the date on which the obligation to issue the Shares terminates pursuant to Article&nbsp;2. IRC shall cause the related prospectus to be amended
or supplemented by a required prospectus supplement pursuant to Rule&nbsp;424 under the Act. Notwithstanding the foregoing, IRC may delay the filing of the registration statement for 180&nbsp;days
after receipt of the request from Trinity, if it furnishes to Trinity a certificate signed by the Chairman of the Board of Directors of IRC stating, it would be seriously detrimental to IRC and its
stockholders for such registration statement to be filed and that it is therefore, essential to delay the filing of the registration statement. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE 4<BR>
REPRESENTATIONS AND WARRANTIES OF IRC  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IRC hereby represents and warrants to Trinity that: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1&nbsp;&nbsp;IRC
is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to
carry on its business as now conducted. IRC is duly qualified to transact business and is in good standing in each jurisdiction in which the failure so to qualify would have a material adverse effect
on IRC. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2&nbsp;&nbsp;All
corporate action on the part of IRC, its officers, directors and stockholders necessary for (a)&nbsp;the authorization, execution and delivery of the Amendment,
(b)&nbsp;the performance of all obligations of IRC hereunder, and (c)&nbsp;the authorization, issuance (or reservation for issuance) and delivery of the Shares being sold hereunder has been taken
and the Amendment constitutes the valid and legally binding obligation of IRC, enforceable against IRC in accordance with its terms. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3&nbsp;&nbsp;The
Shares which are being purchased by Trinity hereunder, when issued, sold and delivered in accordance with the terms hereof, for the consideration expressed herein,
will be duly and validly issued, fully paid and nonassessable and, based in part upon the representations of Trinity in Article&nbsp;5 of this Amendment, will be issued in compliance with applicable
securities laws. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE 5<BR>
REPRESENTATIONS AND WARRANTIES OF TRINITY  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trinity hereby represents, warrants, acknowledges and covenants to IRC as follows: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1&nbsp;&nbsp;Trinity
has the full right, power and authority to enter into this Amendment. This Amendment constitutes Trinity's valid and legally binding obligation, enforceable
against Trinity in accordance with its terms. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2&nbsp;&nbsp;Trinity
is an Accredited Investor as defined under Regulation&nbsp;D promulgated under the Act. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3&nbsp;&nbsp;Trinity
understands and acknowledges that Shares will be issued to Trinity in reliance upon Trinity's representations to IRC, evidenced by Trinity's execution of this
Amendment. Trinity is acquiring the Shares for investment for its own account, not as nominee or agent, and not with a view </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=3,EFW="2083790",CP="THE IMMUNE RESPONSE CORPORATION",DN="2",CHK=116132,FOLIO='3',FILE='DISK038:[02SAN2.02SAN1582]KG1582A.;3',USER='CBABB',CD=';3-JUL-2002;14:17' -->
<A NAME="page_kg1582_1_4"> </A>
<BR>

<P><FONT SIZE=2>
to, or for resale in connection with, any distribution or public offering thereof within the meaning of the Act and state securities laws. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4&nbsp;&nbsp;Trinity
understands and acknowledges that the Shares will not be registered under the Act or qualified under any blue-sky laws on the grounds that the
offering and sale of the Shares contemplated by this Amendment are exempt from registration under the Act pursuant to Section&nbsp;4(2) thereof and exempt from registration or qualification pursuant
to state blue-sky laws, and other applicable laws, and that IRC's reliance upon such exemptions is predicated upon Trinity's representations set forth in this Amendment. Trinity
acknowledges and understands that the Shares must be held indefinitely unless the Shares are subsequently registered under the Act and qualified under applicable blue-sky laws or an
exemption from such registration and such qualification is available. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5&nbsp;&nbsp;Trinity
is aware of the provisions of Rule&nbsp;144 promulgated under the Act which permit limited resale of stock purchased in a private placement subject to the
satisfaction of certain conditions, including, among other things, the existence of a public market for the stock, the availability of certain current public information about IRC, the resale
occurring not less than one year after a party has purchased and paid for the stock to be sold, the sale being through a "broker's transaction" or a transaction directly with a "market maker" and the
number of shares of the stock being sold during any three-month period not exceeding specified limitations. Trinity further acknowledges and understands that IRC may not be satisfying the current
public information requirement of Rule&nbsp;144 at the time Trinity wishes to sell the Shares and, if so, Trinity would be precluded from selling the Shares under Rule&nbsp;144 even if the one
year minimum holding period has been satisfied. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6&nbsp;&nbsp;Trinity
is an investor in securities of companies in the development stage and acknowledges that it is able to fend for itself, can bear the economic risk of its
investment and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Shares. Trinity has been furnished with
and has had access to such information as Trinity considered necessary to make a determination as to the purchase of the Shares. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7&nbsp;&nbsp;Trinity
understands that no public market currently exists for the Shares, and that there can be no guaranty that a public market will ever exist for the Shares. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8&nbsp;&nbsp;Each
certificate representing the Shares may be endorsed with the following legends: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8.1&nbsp;&nbsp;&nbsp;&nbsp;"THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT") AND
ARE "RESTRICTED SECURITIES" AS DEFINED IN RULE 144 PROMULGATED UNDER THE ACT. THE SECURITIES MAY NOT BE SOLD OR OFFERED FOR SALE OR OTHERWISE DISTRIBUTED EXCEPT (i)&nbsp;IN CONJUNCTION WITH AN
EFFECTIVE REGISTRATION STATEMENT FOR THE SHARES UNDER THE ACT OR (ii)&nbsp;IN COMPLIANCE WITH RULE 144, OR (iii)&nbsp;PURSUANT TO AN OPINION OF COUNSEL, SATISFACTORY TO IRC, THAT SUCH REGISTRATION
OR COMPLIANCE IS NOT REQUIRED AS TO SAID SALE, OFFER OR DISTRIBUTION." </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8.2&nbsp;&nbsp;&nbsp;&nbsp;Any
other legends required by applicable law or regulation. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.9&nbsp;&nbsp;Any
legend endorsed on a certificate and the restrictions on transfer instructions with respect to such legended Shares shall be removed, and IRC shall issue a
certificate without such legend to the holder of such Shares if such Shares are registered and sold under the Act and a prospectus meeting the requirements of Section&nbsp;10 of the Act is available
or if such holder satisfies the requirements of Rule&nbsp;144(k) and, where reasonably deemed necessary by IRC, provides IRC with an opinion of counsel for such holder of the Shares, reasonably
satisfactory to IRC, to the effect that (i)&nbsp;such holder, meets the requirements of Rule&nbsp;144(k) or (ii)&nbsp;a public sale, transfer or assignment of such Shares may be made without
registration. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=4,EFW="2083790",CP="THE IMMUNE RESPONSE CORPORATION",DN="2",CHK=31330,FOLIO='4',FILE='DISK038:[02SAN2.02SAN1582]KG1582A.;3',USER='CBABB',CD=';3-JUL-2002;14:17' -->
<A NAME="page_kg1582_1_5"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE 6<BR>
MISCELLANEOUS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1&nbsp;&nbsp;All
terms used, but not defined, in this Amendment shall have the respective meanings set forth in the Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2&nbsp;&nbsp;This
Amendment shall be effective for all purposes as of the Effective Date. Except as otherwise expressly modified by this Amendment, the Agreement shall remain in full
force and effect in accordance with its terms. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3&nbsp;&nbsp;This
Amendment shall be governed by, interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4&nbsp;&nbsp;This
Amendment may be executed in counterparts, each of which shall be deemed to be an original and together shall be deemed to be one and the same document. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN
WITNESS WHEREOF, the undersigned have duly executed and delivered this Amendment effective as of the Effective Date. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="78%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>THE IMMUNE RESPONSE CORPORATION</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="46%" ALIGN="CENTER"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="46%" ALIGN="CENTER"><HR NOSHADE><FONT SIZE=2> Dr.&nbsp;Dennis J. Carlo<BR></FONT> <FONT SIZE=2><I>President and CEO</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
TRINITY MEDICAL GROUP USA,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="46%" ALIGN="CENTER"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="46%" ALIGN="CENTER"><HR NOSHADE><FONT SIZE=2><I>President</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="46%" ALIGN="CENTER"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="46%" ALIGN="CENTER"><HR NOSHADE><FONT SIZE=2><I>Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=5,EFW="2083790",CP="THE IMMUNE RESPONSE CORPORATION",DN="2",CHK=884663,FOLIO='5',FILE='DISK038:[02SAN2.02SAN1582]KG1582A.;3',USER='CBABB',CD=';3-JUL-2002;14:17' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="02SAN1582_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_kg1582_1">Exhibit 10.1</A></FONT><BR>
</UL>
<FONT SIZE=2><A HREF="#toc_kg1582_2">AMENDMENT NO. 3 TO LICENSE AND COLLABORATION AGREEMENT</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=CBABB,SEQ=,EFW="2083790",CP="THE IMMUNE RESPONSE CORPORATION",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
